Development of new quinolines against colorectal carcinoma - EL-MERNISSI, REDA;AJANA, Mohammed Aziz;Bouachrine, Mohammed
32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
16 °P sammeln
  • Broschiertes Buch

Colon cancer is abnormal cells that grow uncontrollably in an organ, resulting in abnormal tissue growth. One of the organs at risk for developing colon cancer cells is the large intestine, or rectum. The current research used computational methods to examine the potential of thirty quinoline compounds as tubulin inhibitors. The main objective of this book is to develop QSAR models to predict the anti-cancer activity of molecules by linking their molecular structures to experimental activities. The models were created using 3D-QSAR, molecular docking, simulation dynamics, and ADMET studies.…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Colon cancer is abnormal cells that grow uncontrollably in an organ, resulting in abnormal tissue growth. One of the organs at risk for developing colon cancer cells is the large intestine, or rectum. The current research used computational methods to examine the potential of thirty quinoline compounds as tubulin inhibitors. The main objective of this book is to develop QSAR models to predict the anti-cancer activity of molecules by linking their molecular structures to experimental activities. The models were created using 3D-QSAR, molecular docking, simulation dynamics, and ADMET studies. The results of the research aid researchers and the World Health Organization in identifying molecules that can be developed into effective anti-cancer agents with inhibitory activity.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. Reda El-Mernissi holds a PhD in chemistry from Moulay Ismail University of Meknes, Morocco. Dr. Reda El-Mernissi is a Qualifying secondary school Physical Chemistry teacher. He has published a number of research articles in various reputed national and international journals and has participated in several conferences on drug design processes.